InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.55
(
-0.18%
)
Bitcoin
65,275.63
(
0.47%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

JJM760

Send PM Follow Ignore
Followers 5
Posts 993
Boards Moderated 0
Alias Born 06/15/2010

JJM760

Re: BTH post# 19659

Monday, 06/11/2012 10:00:18 PM

Monday, June 11, 2012 10:00:18 PM

Post# of 80490
I agree that Novartis prob isn't buying Ariad anytime soon, but I have been wondering something.

If/when Ponatinib is approved, what becomes of Tasigna and Sprycel?

We know the value in generic Gleevec, but why would you prescribe the 2 line drugs when Ponatinib clearly shows better efficacy?

Maybe I am missing something here. Interested in feedback.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up